INTRO

AIMS: Bringing expensive medicines within reach

Addressing unmet patient needs
Helping patients manage disease better
Enabling our partners to ensure our medicines are available where needed
Working with partners to help them succeed

Business

India Branded Generics

North America Generics
Emerging Markets Branded Generics
Europe Generics
Active Pharmaceutical Ingredients (APIs)
Biologics
Aurigene Pharmaceutical Services
AURIGENE DISCOVERY TECHNOLOGIES LIMITED (ADTL) ADTL is our wholly owned
subsidiary and is a clinical stage biotech Company committed to bringing novel therapeutics for the
treatment of cancer and inflammation

Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company located

in Hyderabad, Telangana, India. The company was founded by Kallam Anji Reddy, who previously
worked in the mentor institute Indian Drugs and Pharmaceuticals Limited.[2] Dr. Reddy's manufactures
and markets a wide range of pharmaceuticals in India and overseas. The company has over 190
medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic
kits, critical care, and biotechnology
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other
less-regulated markets that had the advantage of not having to spend time and money on
a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and
Drug Administration (FDA). By the early 1990s, the expanded scale and profitability from these
unregulated markets enabled the company to begin focusing on getting approval from drug regulators
for their formulations and bulk drug manufacturing plants - in more-developed economies. This
allowed their movement into regulated markets such as the US and Europe. In 2014, Dr. Reddy
Laboratories was listed among 1200 of India's most trusted brands according to the Brand Trust
Report 2014, a study conducted by Trust Research Advisory, a brand analytics company. [3]
By 2007, Dr. Reddy's had seven FDA plants producing active pharmaceutical ingredients in India and
seven FDA-inspected and ISO 9001 (quality) and ISO 14001 (environmental management) certified
plants making patient-ready medications – five of them in India and two in the UK. [4]
OPERATIONS

NEWS

 Agreement on Centre of Excellence in flow chemistry at Dr. Reddy’s Institute of Life

Sciences in Hyderabad in the presence of Hon’ble Minister K.T. Rama Rao & Principal
Secretary Jayesh Ranjan

 Intercept Pharmaceuticals settles Ocaliva patent litigation case with Dr Reddy's

 Dr Reddy's buys Novartis cardiovascular brand Cidmus in India for Rs 456 crore
Mankind Pharma to acquire Combihale and Daffy brands from Dr Reddy's Laboratories
Dr Reddy labs get DCGI approval to manfacture & market anti-viral drug 'Molnupiravir'

RATIOS REFERENCE

PRODUCTS
Over the years, the company has significantly grown its portfolio of products across mass and
specialty therapies. Today, our portfolio has over 200 products covering the whole spectrum of
disease areas spanning gastroenterology, oncology, pain management, cardiovascular, dermatology,
urology, nephrology, rheumatology and diabetes. Seven of our brands are listed in “Top-300 of the
Indian Pharma Market” and many others hold leadership positions in their respective categories.

Omez capsule (Omeprazole 20 mg) belongs to a group of drugs called Proton Pump Inhibitors
(PPIs).

Nise tablet (Nimesulide 100 mg) belongs to a group of drugs called NSAIDs (Non Steroidal
Anti-Inflammatory Drugs).


 Stamlo 2.5/5/10 tablets (Amlodipine 2.5/5/10mg) belong to a group of drugs called calcium
channel blockers.

Clamp 625 tablet is a combination of Amoxycillin (500 mg) and Potassium Clavulanate (125
mg). It belongs to the anti-infective class of drugs.

Econorm is a probiotic that contains live cells of Saccharomyces Boulardii (250 mg).

Razo 10/20 tablets (Rabeprazole sodium 10/20) belong to a group of drugs called Proton
Pump Inhibitors (PPIs).

Senquel F is a desensitizing toothpaste and contains potassium nitrate formulation.

Ketorol DT (Ketorolac Tromethamine 10 mg) is a dispersible tablet that belongs to a group of

drugs called analgesics.

Atocor 5/10/20/40/80 mg tablets (Atorvastatin) belong to a group of drugs called statins.

 

Mintop-10 (topical Minoxidil 100 mg) is used to treat male-pattern baldness. Know more.

Venusia cream (aloe vera, squalene, vitamin E) is a moisturizer.

Glimy 1/2/3/4 (Glimepiride 1/2/3/4 mg) tablets belong to a group of drugs called
sulfonylureas (SUs).

Telsartan 20/40/80 (Telmisartan 20/40/80 mg) tablets belong to a group of drugs called
anigiotensin receptor blocker.
MARKET
What percentage of the Indian pharmaceutical market is covered by Dreddy's laboratories

Dr.Reddy's laboratories had a coverage of over 48 percent in the Indian pharmaceutical market as of
financial year 2020. An exponential decrease in the covered market of the company was seen from
financial year 2016.

India has a well-developed healthcare sector with a globally renowned pool of scientists and
engineers. The size of India's pharmaceutical market stood at USD 42 billion in 2021. Globally, India
is the largest provider of generic drugs. The country is the third largest producer of pharmaceutical in
the world, by volume and 14th largest by value. India fulfils approximately 50% of the global demand
for vaccines, 40% of generic demand in the United States and 25% of all medicine in the United
Kingdom.
In the financial year ended March 2021, while North America remained the largest market for Indian
pharmaceutical exports, demand was also witnessed from unconventional export markets. North
America accounted for a share of 34% of the pharmaceutical exports and recorded a growth in exports
to the tune of 12.6% year-on-year. Exports to Canada recorded a growth of 30% year-on-year and
exports to Mexico recorded a growth of 21.4% year-on-year.

In December 2021, the country was hit with the Omicron virus. Omicron, while another addition to
the tragic Covid waves in India, also represents a huge opportunity for the sector. Growth is expected
to be driven by new vaccines and therapeutics to treat the highly transmissible Omicron variant.

In the period April-May 2021, the share of Covid-19-related therapies stood at 44% per cent of the
total Indian pharma market's sales.

COMPETITORS

INDUSTRY OUTLOOK

https://www.ibef.org/industry/pharmaceutical-india

The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021

The Indian Pharmaceuticals industry plays a prominent role in the global pharmaceuticals industry.
India ranks 3rd worldwide for production by volume and 14th by value. The nation is the largest
provider of generic medicines globally, occupying a 20%  share in global supply by volume, and is
the leading vaccine manufacturer globally. India also has the highest number of US-FDA compliant
Pharma plants outside of USA and is home to more than 3,000 pharma companies with a strong
network of over 10,500 manufacturing facilities as well as a highly skilled resource pool.
The pharmaceutical industry in India offers 60,000 generic brands across 60 therapeutic categories.
Major segments include generic drugs, OTC Medicines, API/Bulk Drugs, Vaccines, Contract
Research & Manufacturing, Biosimilars and Biologics.
 Incentives worth INR 21,940 Crore ($3 Bn) are approved 
 Market size expected to reach $65 bn by 2024, and ~$130 bn by 2030
 Expected growth rate of 11-12% (2020-2030) 
 Cost of manufacturing ~ 33% lower than western markets
Indian pharma companies enabled by their price competitiveness and good quality, have made global
mark, with 60% of the world’s vaccines and 20% of generic medicines coming from India. 
100% Foreign Direct Investment (FDI) in the Pharmaceutical sector is allowed under the automatic
route for greenfield pharmaceuticals.
100% FDI in the pharmaceutical sector is allowed in brownfield pharmaceuticals; wherein 74% is
allowed under the automatic route and thereafter through the government approval route.

GOVT INITIATIVE
The Comprehensive Economic Partnership Agreement (CEPA) was signed by India and the United
Arab Emirates (UAE) in February which aims to boost bilateral trade to USD 100 billion in the next
five years

, the draft R&D policy that is under consideration currently has been a welcome, inclusive move by
the government of India, and a much-needed realistic view of present-day and future requirements. It
is yet another step in the increasingly agile and mutually responsive partnership that has formed
between the government and the pharma industry in recent times. The momentum generated by our
unprecedented cooperation during the pandemic, by the consideration of the draft R&D policy with
inputs from all stakeholders, and by timely conversations such as the Global Innovation Summit must
now be maintained and must result in implementation. Indian pharma is in a unique position today to
serve the needs of patients at home in India, in developed markets such as the US, and stand for
access and affordability in Low and Middle-Income Countries (LMICs). Being innovative and
competitive whilst maintaining the highest standards, therefore, would be central to its success.

CHALLENGES ND ROAD AHEAD

 The Indian pharma industry faces lack of research components and real time good
manufacturing practices. This has always been a difficulty for the pharma industry. Pharma
companies should built in such a way that they are equipped with better operational facilities
and abilities.
 Indian pharma companies are not getting proper profits, their earnings are basically very low
as compared to their counterparts in other countries such as the US. Their income is not
sufficient enough to invest money on research component.
 The pharma industry is dependent on China for the supply of raw material for generic
medicines production.
 There is a need for a functional testing laboratory in every state to fasten the work of
specification of raw materials.

The way forward

Looking at the urgent need of the nation for quality healthcare, the pharma industry has to develop
strategies for raw material producing units with user friendly government policy for the small scale
industry. The industry will have to identify researchers/teaching faculty beyond metro cities to get
good ideas and skilled workers from across the country.

DEMAND DRIVERS
Epidemiological factors like 20% increase in the patient pool, new diseases, and lifestyle and
increasing prevalence of lifestyle diseases will boost the demand for pharmaceuticals in India.
TRENDS
https://docmode.org/top-growth-drivers-of-indian-pharmaceutical-industry-in-2020/